Medeva may be the cure Fisons needs

AFTER MONTHS of bold restructuring that has changed the direction of the company, Fisons is taking its biggest gamble yet. Its plan to take over Medeva, a rival drugs company, is not only a clever strategic move - the entire future of Fisons may also hang on its success.

If it succeeds, the rapid conversion of Fisons from the sick man of the pharmaceuticals sector to a company with a bright future will be complete. If it fails, the restructuring will have left Fisons looking extremely exposed and possibly lacking the expertise to survive in its field.

That the company appears a credible predator for Medeva at all is a tribute to its resurrection. A year ago it was widely seen in the stock market as lacking direction or strategy. Sales were falling and it had few new products in development to make up the shortfall. Almost every large drug company in Europe and the United States had examined it as a takeover target and rejected it. It desperately needed strong medicine to survive.

This is what Stuart Wallis, the chief executive brought in late last year, has provided. In the space of a few weeks he dealt with the loss- making scientific instruments operation by selling it rather than shutting it down. Then, in an almost heretical move for a drugs company, he sold the research and development arm to Astra, the Swedish company, for £202m. The laboratory supplies arm is also expected to be sold.

All of this will raise in the region of £470m in cash for the company while saving it some £70m a year that used to go on research spending. These were the kind of bold decisions that many believe could only have been taken by an outsider to the industry. Mr Wallis was one of the directors involved in changing Bowater, the struggling paper company, into a successful packaging group. He has no background in pharmaceuticals.

What he has done, however, is to turn Fisons from a conventional drugs company researching its own products into one that buys in products and uses its substantial sales force to market them. This strips out the huge development costs of new drugs although it now means the company must find drugs in a late stage of development to "license in" from outside and then market.

But Mr Wallis's restructuring can be seen in another light, too. "It is classic conglomerate financing," says one analyst. "It's the kind of thing Bowater might have done. You write down the assets, sell off the loss-making bits, boost the share price, and then make an acquisition that will improve the earnings per share."

Either way, a link with Medeva makes perfect sense for Fisons. It would not only get its takeover, it would also be buying the company on which it is modelling itself. Medeva, under its chairman, Bernard Taylor, a former Glaxo executive, has grown rapidly as a drug marketing company. It has bought in several successful "late-stage development" drugs, including respiratory drugs and a promising hepatitis B vaccine that is to be marketed soon.

Medeva's sales last year were £239m compared with £450m at Fisons. But while Medeva's sales have soared sixfold in the last five years and growth could reach 20 per cent, Fisons's sales growth is steadily falling into single figures.

Until Fison's transformation, Medeva was virtually the only UK drugs company occupying this niche in the sector. To find, buy in and exploit successful drugs in an increasingly competitive market requires management with long experience of pharmaceuticals and wide contacts in the industry. Led by Mr Taylor, Medeva has this.

Fisons does not. All its experience is focused on research and development rather than buying new drugs on the open market. Capturing Medeva's expertise would solve that at a stroke.

"The easy bit for Fisons was changing the company," says Peter Laing, analyst at Salomon Brothers. "Now it has to survive in its new form. It will be left in an exposed position if it doesn't pull off the deal with Medeva. Companies would not rush to buy Fisons, even though it is more attractive now."

This is why Fisons may be willing to pay £3 a share or more for Medeva, valuing the company at £900m, compared with a current market price below 250p. It is also why the deal may in the end look more like a merger or a reverse takeover than an outright purchase by Fisons. The stock market would almost certainly take more comfort from a combined company run largely by Medeva executives than one controlled by the Fisons team. Indeed, the outcome of the deal talks will almost certainly hinge partly on how the jobs will be shared out.

But while Fisons has everything to gain, Medeva's motive for the deal is less clear. The fit between products, such as its respiratory products and Fisons' asthma drugs, makes sense. Moreover, Fisons brings a large European sales force, which Medeva lacks since most of its marketing effort is in the US.

Yet in the near term, its sales and earnings will almost certainly be impaired by linking up with Fisons. Pushing up the sales of the combined group will also become a mammoth task that will require the company to find some remarkable new drugs - not an easy job, even for Medeva's talented management.

For these reasons, Medeva will have to drive a hard bargain to justify the deal. It is said to have set a minimum of 280p in the negotiations so far, but its US shareholders - about half the investor base - may demand more. In the end Medeva may find it hard to accept anything less than £3 per share. Fisons may, ultimately, have to scrape together substantially more to clinch the deal.

Even then, the takeover is by no means in the bag. Most analysts give it a 50-50 chance. But if Mr Wallis does not pull it off and his company has to face the future on its own, things may start to look bleak for Fisons.

Life & Style
Sampling wine in Turin
food + drink...and abstaining may be worse than drinking too much, says scientist
Arts & Entertainment
Game of Thrones writer George R.R. Martin has been working on the novels since the mid-Nineties
books
Sport
Jose Mourinho, Chelsea players celebrate Demba Ba's goal and Gus Poyet
sportLive coverage of today's final game between Chelsea and Sunderland
News
Brand said he
people
VIDEO
Sport
Roger Federer celebrates his victory over Novak Djokovic in the Monte Carlo Masters
sport
Arts & Entertainment
Kingdom Tower
architecture
Voices
Actor Zac Efron
voicesTopless men? It's as bad as Page 3, says Howard Jacobson
Arts & Entertainment
The monster rears its head as it roars into the sky
film
Voices
For the Love of God (2007) The diamond-encrusted skull that divided the art world failed to sell for
its $100m asking price. It was eventually bought by a consortium
which included the artist himself.
voicesYou can shove it, Mr Webb – I'll be having fun until the day I die, says Janet Street-Porter
Sport
Mercedes driver Lewis Hamilton of Britain drives in the rain during the qualifying session of the Chinese Formula One Grand Prix in Shanghai
sport
Extras
indybestFake it with 10 best self-tanners
Arts & Entertainment
Madonna in her music video for 'Like A Virgin'
music... and other misheard song lyrics
News
Much of the colleges’ land is off-limits to locals in Cambridge, with tight security
educationAnd has the Cambridge I knew turned its back on me?
Sport
Steven Gerrard had to be talked into adopting a deeper role by his manager, Brendan Rodgers
sportThe city’s fight for justice after Hillsborough is embodied in Steven Gerrard, who's poised to lead his club to a remarkable triumph
News
peopleOrlando Bloom the pin-up hero is making a fresh start
News
Who makes you happy?
happy listSend your nominations now for the Independent on Sunday Happy List
Life & Style
The North Korean TV advert for Taedonggang beer, that became a YouTube hit
food + drinkAnd what did it take to set up a taste test back in Wiltshire?
Arts & Entertainment
filmLife for Leslie Mann's can be challenging sometimes
Voices
For music lovers: John Cusack with his vinyl collection in 'High Fidelity'
voices...but don't forget rest of the year
Have you tried new the Independent Digital Edition iPad app?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

1st Line Helpdesk Engineer Apprentice

£150.00 per week: QA Apprenticeships: This company has been providing on site ...

Telesales & Sales Support Apprentice

£221.25 per week: QA Apprenticeships: This company is a well established Inter...

Client Relationship Manager - SQL, Python

£40000 - £50000 per annum: Harrington Starr: Client Relationship Manager - SQL...

**Financial Services Tax**

£35000 - £50000 per annum: Pro-Recruitment Group: Take your chance to join the...

Day In a Page

How I brokered a peace deal with Robert Mugabe: Roy Agyemang reveals the delicate diplomacy needed to get Zimbabwe’s President to sit down with the BBC

How I brokered a peace deal with Robert Mugabe

Roy Agyemang reveals the delicate diplomacy needed to get Zimbabwe’s President to sit down with the BBC
Video of British Muslims dancing to Pharrell Williams's hit Happy attacked as 'sinful'

British Muslims's Happy video attacked as 'sinful'

The four-minute clip by Honesty Policy has had more than 300,000 hits on YouTube
Church of England-raised Michael Williams describes the unexpected joys in learning about his family's Jewish faith

Michael Williams: Do as I do, not as I pray

Church of England-raised Williams describes the unexpected joys in learning about his family's Jewish faith
A History of the First World War in 100 moments: A visit to the Front Line by the Prime Minister's wife

A History of the First World War in 100 moments

A visit to the Front Line by the Prime Minister's wife
Comedian Jenny Collier: 'Sexism I experienced on stand-up circuit should be extinct'

Jenny Collier: 'Sexism on stand-up circuit should be extinct'

The comedian's appearance at a show on the eve of International Women's Day was cancelled because they had "too many women" on the bill
Cannes Film Festival: Ken Loach and Mike Leigh to fight it out for the Palme d'Or

Cannes Film Festival

Ken Loach and Mike Leigh to fight it out for the Palme d'Or
The concept album makes surprise top ten return with neolithic opus from Jethro Tull's Ian Anderson

The concept album makes surprise top ten return

Neolithic opus from Jethro Tull's Ian Anderson is unexpected success
Lichen is the surprise new ingredient on fine-dining menus, thanks to our love of Scandinavian and Indian cuisines

Lichen is surprise new ingredient on fine-dining menus

Emily Jupp discovers how it can give a unique, smoky flavour to our cooking
10 best baking books

10 best baking books

Planning a spot of baking this bank holiday weekend? From old favourites to new releases, here’s ten cookbooks for you
Jury still out on Manchester City boss Manuel Pellegrini

Jury still out on Pellegrini

Draw with Sunderland raises questions over Manchester City manager's ability to motivate and unify his players
Ben Stokes: 'Punching lockers isn't way forward'

Ben Stokes: 'Punching lockers isn't way forward'

The all-rounder has been hailed as future star after Ashes debut but incident in Caribbean added to doubts about discipline. Jon Culley meets a man looking to control his emotions
Mark Johnston: First £1 million jackpot spurs him on

Mark Johnston: First £1 million jackpot spurs him on

The most prize money ever at an All-Weather race day is up for grabs at Lingfield on Friday, and the record-breaking trainer tells Jon Freeman how times have changed
Ricky Gervais: 'People are waiting for me to fail. If you think it's awful, then just don't watch it'

Ricky Gervais: 'People are waiting for me to fail'

As the second series of his divisive sitcom 'Derek' hits screens, the comedian tells James Rampton why he'll never bow to the critics who habitually circle his work
Mad Men series 7, TV review: The suits are still sharp, but Don Draper has lost his edge

Mad Men returns for a final fling

The suits are still sharp, but Don Draper has lost his edge
Google finds a lift into space will never get off the ground as there is no material strong enough for a cable from Earth into orbit

Google finds a lift into space will never get off the ground

Technology giant’s scientists say there is no material strong enough for a cable from Earth into orbit